Enterprise Value

80.18M

Cash

54.42M

Avg Qtr Burn

-51.8M

Short % of Float

8.61%

Insider Ownership

7.73%

Institutional Own.

51.18%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
TX-200 Details
Kidney disease, Kidney transplantation

Phase 1/2

Data readout

SB-525 / PF-07055480 (giroctocogene fitelparvovec) Details
Blood disorder, Rare genetic disease, Hemophilia, Rare diseases

Phase 1/2

Data readout

ST-920 (isaralgagene civaparvovec) Details
Fabry disease, Rare genetic disease

Phase 1/2

Update

BIVV003 (SAR445136) Details
Sickle cell disease, Blood disorder

Failed

Discontinued

ST-400 Details
Blood disorder, Beta thalessemia

Failed

Discontinued

SB-913 Details
Genetic disorder, Rare diseases, Mucopolysaccharidoses, Rare genetic disease, Mucopolysaccharidosis type II

Failed

Discontinued